4.3 Article

Parkinson's disease between internal medicine and neurology

期刊

JOURNAL OF NEURAL TRANSMISSION
卷 123, 期 1, 页码 3-17

出版社

SPRINGER WIEN
DOI: 10.1007/s00702-015-1443-z

关键词

Parkinson's disease; Internal disease; Comorbidity; Side effects; Interactions

资金

  1. Abbvie
  2. Desitin
  3. Medtronic
  4. TEVA
  5. UCB Pharma
  6. Zambon
  7. Abbott
  8. Bayer Health Care
  9. Boehringer/Ingelheim
  10. Brittania
  11. Cephalon
  12. GSK
  13. Lundbeck
  14. Merck-Serono
  15. Novartis
  16. Orion
  17. Pfizer
  18. Valeant

向作者/读者索取更多资源

General medical problems and complications have a major impact on the quality of life in all stages of Parkinson's disease. To introduce an effective treatment, a comprehensive analysis of the various clinical symptoms must be undertaken. One must distinguish between (1) diseases which arise independently of Parkinson's disease, and (2) diseases which are a direct or indirect consequence of Parkinson's disease. Medical comorbidity may induce additional limitations to physical strength and coping strategies, and may thus restrict the efficacy of the physical therapy which is essential for treating hypokinetic-rigid symptoms. In selecting the appropriate medication for the treatment of any additional medical symptoms, which may arise, its limitations, contraindications and interactions with dopaminergic substances have to be taken into consideration. General medical symptoms and organ manifestations may also arise as a direct consequence of the autonomic dysfunction associated with Parkinson's disease. As the disease progresses, additional non-parkinsonian symptoms can be of concern. Furthermore, the side effects of Parkinson medications may necessitate the involvement of other medical specialists. In this review, we will discuss the various general medical aspects of Parkinson's disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据